Klimas, Nancy G, Broderick, Gordon, Fletcher, Mary Ann · Brain, behavior, and immunity · 2012 · DOI
Quick Summary
This review examines blood tests and biological markers that might help diagnose ME/CFS, since current diagnosis relies only on symptoms. The researchers found that multiple body systems—including the immune system, stress hormones, and nervous system—appear to be disrupted in ME/CFS patients. However, no single test yet reliably identifies the condition, suggesting ME/CFS may involve complex changes across several systems rather than one simple cause.
Why It Matters
ME/CFS currently lacks objective diagnostic tests, making diagnosis difficult and delaying treatment. This review highlights the biological basis of ME/CFS—showing it involves real changes in immune, nervous, and hormone systems—which validates patients' experiences and could guide future research toward testable biomarkers that enable earlier, more accurate diagnosis.
Observed Findings
Evidence of immune system activation and inflammatory markers in ME/CFS patients
Dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress hormones
Autonomic nervous system dysfunction affecting heart rate, blood pressure, and other automatic functions
Neuroendocrine dysregulation affecting multiple hormone systems
Biomarkers distributed across multiple body systems rather than localized to a single organ
Inferred Conclusions
ME/CFS is a multisystem disorder involving simultaneous disruption of immune, endocrine, and nervous system functions
No single biomarker is sufficient for diagnosis; an integrated molecular profile across systems is needed
Objective biological markers exist but have not yet been standardized or validated for clinical diagnostic use
Developing effective treatments requires first establishing a clear molecular signature of the disease
Remaining Questions
Which specific biomarker combinations would reliably distinguish ME/CFS from other fatiguing illnesses in clinical practice?
What This Study Does Not Prove
This review does not prove which specific biomarkers actually cause ME/CFS versus which are consequences of the illness. It also does not establish a single definitive diagnostic test or demonstrate that any individual biomarker is reliably useful in clinical practice. The authors emphasize that finding multiple abnormalities does not yet explain how they interact to produce ME/CFS.